Neratinib/T-DM1 Combo Shows Promise in HER2-Positive Breast Cancer
The combination of neratinib and T-DM1 induced an overall response rate of 60% in previously-treated women with HER2-positive metastatic breast cancer.
Source: OncLive
The combination of neratinib and T-DM1 induced an overall response rate of 60% in previously-treated women with HER2-positive metastatic breast cancer.
Source: OncLive
Your Technology Source, Your Technology Team
Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more
Contact Us: contact@crwetech.com
Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure
CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform
Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!
Contact Us: contact@crweworld.com